Figure 4 — Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy

Research Paper|Volume 13, Issue 13|pp. 17638–17654

Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy

100%

Figure 4.Forest plot for the HRs of progression-free survival (PFS) in gastric cancer patients with systemic therapy between low and high pretreatment NLR. “D+L” means DerSimonian and Laird method. “I-V” means generic inverse variance method.